What is the role of high-dose chemotherapy in the era of targeted therapies?

Journal of Clinical Oncology

Volumn 22, Issue 12, 2004, Pages 2263-2266

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; TAXANE DERIVATIVE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DRUG MEGADOSE; DRUG TOLERABILITY; EDITORIAL; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MEDICAL INFORMATION; META ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; NOTE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 2942750359     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.927     Document Type: Editorial

References (29)

1. Ariel IM: Treatment of disseminated cancer by intravenous hydroxyurea and autogenous bone-marrow transplants: Experience with 35 patients. J Surg Oncol 7:331-335, 1975
2. Spitzer G, Dicke KA, Verma DS, et al: High dose chemotherapy with autologous bone marrow transfusion. Exp Hematol 7:38-53, 1979 (suppl 5)
3. Spitzer G, Dicke KA, Litam J, et al: High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors. Cancer 45:3075-3085, 1980
4. Stewart PS: Autologous bone marrow transplantation in metastatic breast cancer. Breast Cancer Res Treat 2:85-92, 1982
5. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
6. Buzdar AU, Smith TL, Marcus CE, et al: Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer, in Recent Results in Cancer Research (vol 96), Berlin, Germany, 1984, pp 141-147
7. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
8. Hryniuk WM, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
9. Rahman Z, Frye DK, Buzdar AU, et al: Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15:3171-3177, 1997
10. Crump M, Goss PE, Prince M, et al: Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 14:66-69, 1996
11. Hortobagyi GN, Buzdar AU, Theriault RL, et al: Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92:225-233, 2000
12. Rodenhuis S, Richel DJ, van der Wall E, et al: Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352:515-521, 1998
13. Peters W, Rosner G, Vredenburgh J, et al: A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 2)
14. Peters WP, Rosner G, Vredenburgh J, et al: Updated results of a prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 20:21a, 2001 (abstr 81)
15. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial - Scandinavian Breast Group 9401 study. Lancet 356:1384-1391, 2000
16. Crown JP, Lind M, Gould A, et al: High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer (BC) and 4 or more involved axillary lymph nodes (4+ LN): The Anglo-Celtic I study. Proc Am Soc Clin Oncol 21:42a, 2002 (abstr 166)
17. Gianni A, Bonadonna G: Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with > 3 positive nodes. Proc Am Soc Clin Oncol 20:21a, 2001 (abstr 80)
18. Roche HH, Pouillard P, Meyer N, et al: Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N>7) breast cancer patients: The Pegase 01 Trial. Proc Am Soc Clin Oncol 20:26a, 2001 (abstr 102)
19. Rodenhuis S, Bontenbal M, Beex LV, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7-16, 2003
20. Tallman MS, Gray R, Robert NJ, et al: Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349:17-26, 2003
21. Zander AR, Kroger N, Schmoor C, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 22:2273-2283, 2004
22. Roche H, Viens P, Biron P, et al: High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 10:42-47, 2003
23. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
24. Nabholtz J-M, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21:36a, 2002
25. The ATAC Trialists' Group.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
26. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
27. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
28. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
29. Poole CJ, Earl HM, Dunn JA, et al: NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc Am Soc Clin Oncol 22:4, 2003 (abstr 13)